Akero (AKRO) director trades: 3,000 options exercised, 3,000 shares sold

Jane Henderson, a director of Akero Therapeutics (AKRO), reported insider transactions dated 08/12/2025 showing linked non-derivative and derivative activity.

Accepted by SEC EDGAR 08/12/2025 - 08:32 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Jane Henderson, a director of Akero Therapeutics (AKRO), reported insider transactions dated 08/12/2025 showing linked non-derivative and derivative activity. The filing shows an acquisition of 3,000 common shares associated with a stock option having a conversion/exercise price of $7.009, and a sale of 3,000 common shares at $47.457. Following the reported transactions the filing shows she beneficially owned 9,398 shares of common stock directly. The disclosure also states that the related options are vested and currently exercisable.

Insights

Financial Analyst

TL;DR: Director exercised options linked to 3,000 shares and sold 3,000 shares; transactions appear routine and not clearly material.

The Form 4 shows a simultaneous acquisition tied to options at a $7.009 conversion/exercise price and a contemporaneous sale of 3,000 shares at $47.457. After these entries the filer is reported as beneficially owning 9,398 shares. The filing also confirms the options are vested and exercisable. This pattern is consistent with an option exercise plus sale; the absolute amounts disclosed are modest and the filing contains no indication of broader corporate developments.

Corporate Governance Expert

TL;DR: The disclosure is clear and timely: a director recorded option-related activity and a matching sale; governance transparency maintained.

The report identifies the reporting person as a director and indicates the filing was made by one reporting person. It lists both non-derivative and derivative entries tied to 3,000 shares and notes the options are vested and exercisable. From a governance viewpoint, the filing meets Section 16 reporting requirements by disclosing the exercise/sale activity; no additional governance concerns or material changes are disclosed in this filing.

Insider Trade Summary

Exercise and Sale: 3,000 shares ($121K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Henderson Jane

Role Director

Sold 3,000 shs ($142K)

Approx. gross sale proceeds $142K

Approx. exercise cost $21K

Approx. pre-tax spread $121K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,000	$0.00	$0.00
Exercise	Common Stock	3,000	$7.009	$21K
Sale	Common Stock	3,000	$47.457	$142K

Holdings After Transaction: Stock Option (Right to Buy) — 11,797 contracts (Direct); Common Stock — 9,398 shares (Direct)

Footnotes (1)

1. F1. The options are vested and currently exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transactions did Jane Henderson report on Form 4 for AKRO?

The filing reports an acquisition tied to options of 3,000 common shares (conversion/exercise price $7.009) and a sale of 3,000 common shares at $47.457.

How many AKRO shares does Jane Henderson beneficially own after the reported transactions?

Following the reported transactions the filing shows 9,398 shares of common stock beneficially owned directly.

What was the conversion/exercise price of the reported stock option?

The reported conversion/exercise price for the option is $7.009.

Are the options reported by Jane Henderson exercisable?

Yes. The filing explicitly states: the options are vested and currently exercisable.

What is Jane Henderson's relationship to Akero Therapeutics (AKRO)?

The Form 4 identifies Jane Henderson as a director of Akero Therapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Henderson Jane

(Last) (First) (Middle)

601 GATEWAY BOULEVARD

SUITE 350

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akero Therapeutics, Inc. [ AKRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		M		3,000	A	$7.009	12,398	D
Common Stock	08/12/2025		S		3,000	D	$47.457	9,398	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.009	08/12/2025		M			3,000	(1)	04/02/2029	Common Stock	3,000	$0.00	11,797	D

Explanation of Responses:

1. The options are vested and currently exercisable.

	/s/ Jonathan Young, Attorney-in-Fact	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.